Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Next Previous
Search
Trial Profile

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Carboplatin; Dexamethasone; Etoposide; Idarubicin; Ifosfamide; Rituximab; Vincristine
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 05 Aug 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
    • 02 Jul 2021 Status changed from active, no longer recruiting to completed.
    • 22 Oct 2020 This trial has been suspended in Sweden, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top